Featured News

New Phase 2 Clinical Trial: TEV-CeD2 Study

The Celiac Disease Foundation on May 22 awarded its first Celiac Disease Policy Leadership Award to U.S. Representative Betty McCollum (MN-04) for her distinguished service and advocacy on behalf of the celiac disease patient community. Among other initiatives, she established the bipartisan Congressional Celiac Disease Caucus, which has significantly increased federal recognition of celiac disease.

The future of celiac disease research is promising, with exciting advancements in diagnosis and therapies presented at the 2024 Digestive Disease Week® (DDW) conference in Washington, D.C. Read on for updates the Celiac Disease Foundation team gathered from lectures, posters, and panel discussions at the conference.

In March, our Celiac Disease Foundation staff—most of whom are lived experience experts—headed to the halls of Congress for our annual round of bipartisan meetings with key members of Congress to advocate for the interests of our patient and research communities.

The SynCeD Study is looking for adult volunteers with celiac disease to join a phase 2a clinical trial. Your participation could make a difference. 

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

On April 9, 2019, Marilyn G. Geller, CEO of the Celiac Disease Foundation, testified before the House Appropriations Subcommittee overseeing the funding for the Department of Health and Human Services, including the National Institutes of Health (NIH).